Moomoo AI 已提取核心訊息
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on February 20, 2024, the submission of three international patent applications. These applications, filed under the Patent Cooperation Treaty (PCT), are in collaboration with SciSparc Ltd., a company focusing on central nervous system disorders. The patents pertain to novel combinations of classic psychedelic substances including LSD, psilocybin, DMT, and SciSparc's proprietary compound Palmitoylethanolamide (PEA). Initially filed as provisional applications with the USPTO, these submissions expand Clearmind's intellectual property portfolio, which now comprises 27 granted patents and 24 pending applications across 15 families. The company's CEO, Dr. Adi Zuloff-Shani, emphasized the strategic move to protect their compounds in multiple countries, reinforcing their position in the psychedelic market. Clearmind, which is listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange, aims to develop and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements, particularly targeting alcohol use disorder among other health issues.
Clearmind Medicine Inc., a biotech company specializing in psychedelic-derived therapeutics, announced on February 20, 2024, the submission of three international patent applications. These applications, filed under the Patent Cooperation Treaty (PCT), are in collaboration with SciSparc Ltd., a company focusing on central nervous system disorders. The patents pertain to novel combinations of classic psychedelic substances including LSD, psilocybin, DMT, and SciSparc's proprietary compound Palmitoylethanolamide (PEA). Initially filed as provisional applications with the USPTO, these submissions expand Clearmind's intellectual property portfolio, which now comprises 27 granted patents and 24 pending applications across 15 families. The company's CEO, Dr. Adi Zuloff-Shani, emphasized the strategic move to protect their compounds in multiple countries, reinforcing their position in the psychedelic market. Clearmind, which is listed on Nasdaq, the Canadian Securities Exchange, and the Frankfurt Stock Exchange, aims to develop and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements, particularly targeting alcohol use disorder among other health issues.
專門從事迷幻藥衍生療法的生物技術公司Clearmind Medicine Inc. 於2024年2月20日宣佈提交三項國際專利申請。這些申請是根據《專利合作條約》（PCT）提交的，是與專注於中樞神經系統疾病的公司ScisPARC Ltd. 合作的。這些專利涉及經典迷幻物質的新組合，包括迷幻藥、迷幻藥、DMT和ScisPARC的專有化合物棕櫚酰乙醇胺（PEA）。這些提交最初是作爲臨時申請向美國專利商標局提交的，擴大了Clearmind的知識產權組合，現在包括15個家族的27項已獲授權的專利和24項待處理的申請。該公司首席執行官阿迪·祖洛夫-沙尼博士強調了保護其化合物在多個國家的戰略舉措，以鞏固他們在迷幻市場中的地位。Clearmind在納斯達克、加拿大證券交易所和法蘭克福證券交易所上市，旨在開發和商業化迷幻藥類化合物，作爲受管制藥物、食品或補品，特別是針對酒精使用障礙和其他健康問題。
專門從事迷幻藥衍生療法的生物技術公司Clearmind Medicine Inc. 於2024年2月20日宣佈提交三項國際專利申請。這些申請是根據《專利合作條約》（PCT）提交的，是與專注於中樞神經系統疾病的公司ScisPARC Ltd. 合作的。這些專利涉及經典迷幻物質的新組合，包括迷幻藥、迷幻藥、DMT和ScisPARC的專有化合物棕櫚酰乙醇胺（PEA）。這些提交最初是作爲臨時申請向美國專利商標局提交的，擴大了Clearmind的知識產權組合，現在包括15個家族的27項已獲授權的專利和24項待處理的申請。該公司首席執行官阿迪·祖洛夫-沙尼博士強調了保護其化合物在多個國家的戰略舉措，以鞏固他們在迷幻市場中的地位。Clearmind在納斯達克、加拿大證券交易所和法蘭克福證券交易所上市，旨在開發和商業化迷幻藥類化合物，作爲受管制藥物、食品或補品，特別是針對酒精使用障礙和其他健康問題。
有用
沒用